BCL2 and cancer: Venetoclax, currently approved for use in patients with chronic lymphocytic leukemia [18], navitoclax, TW-37, GX15-070 and BM-1197, are Bcl-2 or Bcl-xL inhibitors with anticancer activity in a broad range of cancer types [8].